Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Juvenile Macular Degeneration (Stargardt Disease) 30
Oct 26, 2017: Lin BioScience Receives US FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease 30
Sep 10, 2017: Acucela Receives New Patent Covering Method of Use for Emixustat Hydrochloride 30
Clinical Trial Profile Snapshots 31
Appendix 46
Abbreviations 46
Definitions 46
Research Methodology 47
Secondary Research 47
About GlobalData 48
Contact Us 48
Source 48

List of Tables
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 10
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Europe, Top Countries, 2017* 11
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials, G7 Countries (%), 2017* 15
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials, E7 Countries (%), 2017* 18
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Phase, 2017* 21
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29

List of Figures
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 10
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Europe, Top Countries (%), 2017* 11
Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials, G7 Countries (%), 2017* 15
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials, E7 Countries (%), 2017* 18
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
GlobalData Methodology 47

Companies Mentioned
- Astellas Pharma Inc
- Alkeus Pharmaceuticals Inc
- Kubota Pharmaceutical Holding
- Visum Therapeutics
- Vision Medicines Inc
- Sanofi
- Ophthotech Corp
- MD Stem Cells
- Lin Bioscience Inc
- CHA Bio & Diostech Co Ltd